ImmunoCellular taps PharmaCell to manufacture dendritic cell-based vaccine for trial

By Zachary Brennan

- Last updated on GMT

ImmunoCellular taps PharmaCell to manufacture dendritic cell-based vaccine for trial
European CMO PharmaCell B.V. has finalized an agreement with ImmunoCellular Therapeutics to support its pivotal phase III clinical trial in Europe with ICT-107, a dendritic cell-based vaccine in development for glioblastoma multiforme, a form of brain cancer. 

Under the terms of the agreement, PharmaCell will perform a technology transfer from its US-based contract manufacturing partner to its newly acquired Geleen facility in the Netherlands to support the clinical trial with ICT-107. The deal is the first sign that PharmaCell is filling capacity at the cell therapy production facility, which was purchased from TiGenix last year​, and which currently is used to manufacture TiGenix’s ChondroCelect, a product for cartilage repair.

Alexander Vos, CEO of PharmaCell, told Outsourcing-Pharma.com: “PharmaCell has experience in the field of producing dendritic cell-based vaccines due to its long-term relationship with Dendreon​,” which it worked with since 2011. Denderon is now bankrupt.

Our sites in Maastricht and Geleen are both fully licensed for the commercial production of cell-based therapeutics in the European Union. The size of our facility in Geleen, with 45,000 square feet, enables us to offer customers the opportunity to expand to the volumes required for commercial scale production​,” he added.

He also said that the new work “confirms that our new Geleen facility is indeed viewed by industry experts as meeting the requirements and client expectations for late clinical stage and commercial manufacturing for ATMPs [Advanced-therapy medicinal products]​.”

Both of the company’s manufacturing sites are GMP-licensed and inspected by EMA for commercial production of ATMPs (Advanced Therapy Medicinal Products).

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us

Products

View more

Webinars